| 763788 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
443 Open-label, phase 2 study to assess the safety of mogamulizumab at 2 mg/kg Q4W maintenance dosing in patients with relapsed/refractory MF/SS subtypes of CTCL |
2021-11-01 |
10.1136/jitc-2021-sitc2021.443 |
Dwyer Karen, Meier Roland, Hruska Matthew, Fox Floyd, Ito Takahiro |
| 763787 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
613 9-ING-41, a selective small molecule inhibitor of Glycogen Synthase Kinase-3 beta (GSK-3beta), may enhance neuroblastoma immunogenicity |
2021-11-01 |
10.1136/jitc-2021-sitc2021.613 |
Markovska Angela, Cavalcante Ludimila, Giles Francis, Boes Marianne |
| 763786 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
627 ImmunoAtlas: an online public portal for sharing, visualizing, and referencing multiplex immunohistochemistry/immunofluorescence (mIHC/IF) images and results for immuno-oncology |
2021-11-01 |
10.1136/jitc-2021-sitc2021.627 |
Joey Lee Jia Ying, Yeong Joe, Nadia Lee Li Wen Justina, Loo Lit-Hsin, Dong Jiahui |
| 763785 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
270 Anti-CD47 immunotherapy as a therapeutic strategy for the treatment of breast cancer brain metastasis |
2021-11-01 |
10.1136/jitc-2021-sitc2021.270 |
Mackert Jessica, Stirling Elizabeth, Kooshki Mitra, Zhao Dawen, Thomas Alexandra, Lesser Glenn, Triozzi Pierre, Soto-Pantoja David |
| 763784 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
298 Tumor cell-intrinsic mTORC1 signaling through raptor makes melanoma and ovarian cancer immunotherapy resistant by regulating interferon-gamma responsiveness and promoting tumor-initiating cells |
2021-11-01 |
10.1136/jitc-2021-sitc2021.298 |
Gupta Harshita, Kari Suresh, Salinas Emily, Bai Haiyan, Osta Erica, Kornepati Anand, Wang Juan, Zhang Xinyue, Chen Yidong, Vadlamudi Ratna, Curiel Tyler |
| 763783 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
327 Development and validation of a neoantigen-specific T cell gene signature to identify antitumor T cells in lung cancer and melanoma |
2021-11-01 |
10.1136/jitc-2021-sitc2021.327 |
Zhang Jiajia, Caushi Justina, Oliveira Giacomo, Zhang Boyang, Ji Zhicheng, Naidoo Jarushka, Marrone Kristen, Taube Janis, Hellmann Matthew, Brahmer Julie, Merghoub Taha, Forde Patrick, Yegnasubramanian Srinivasan, Wu Catherine, Ji Hongkai, Pardoll Andrew, Smith Kellie |
| 763782 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
264 SIRPa blockade synergizes with radiation therapy in murine breast cancer models |
2021-11-01 |
10.1136/jitc-2021-sitc2021.264 |
Charpentier Maud, Lhuillier Claire, Mota Ines, Trombetta Sergio, Demaria Sandra |
| 763781 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
698 PD-L1 targeted CD28 costimulatory bispecific antibodies enhance T cell activation in solid tumors |
2021-11-01 |
10.1136/jitc-2021-sitc2021.698 |
Zeng Veronica, Moore Gregory, Diaz Juan, Bonzon Christine, Avery Kendra, Love Ruschelle, Dragovich Matthew, Rashid Rumana, Leung Irene, Hackett Michael, Qi Jing, Bakhit Charles, Muchhal Umesh, Barlow Norman, Desjarlais John, Hedvat Michael |
| 763780 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
155 CD5 knockout enhances the potency of multiplex base-edited allogeneic anti-CD5 CAR T-cell therapy for the treatment of T-cell malignancies |
2021-11-01 |
10.1136/jitc-2021-sitc2021.155 |
Yang Yinmeng (Amy), Murray Ryan, Camblin Adam, Musenge Faith, Coholan Lindsey, Naniong MarkVic, Sweezy David, Haskett Scott, Young Lauren, Zhang Yingying, Costa Amanda, Wu Hui, Ladd Alden, Barrera Luis, Schlehuber Lisa, Smith Sarah, Poh Yeh-Chuin, Ciaramella Giuseppe, Gehrke Jason |
| 763779 |
JOURNAL FOR IMMUNOTHERAPY OF CANCER |
516 Peripheral and tumoral immune activity in the expansion part of the first-in-human DuoBody®-PD-L1×4–1BB (GEN1046) trial |
2021-11-01 |
10.1136/jitc-2021-sitc2021.516 |
Aix Santiago Ponce, Calvo Emiliano, Moreno Victor, Garralda Elena, Cervantes Andrés, Ramalingam Suresh, Pérez José Trigo, LoRusso Patricia, Furqan Muhammad, Cho Daniel, Muik Alexander, Lagkadinou Eleni, Türeci Özlem, Couto Suzana, Pencheva Nora, Forssmann Ulf, Şahin Uğur, Ahmadi Tahamtan, Higgs Brandon, Jure-Kunkel Maria, Melero Ignacio |
